Page 258

Catalogue_WEB_WoP_Jun16

Clinical Chemistry Zonisamide Quantitative immunoassay for determination of zonisamide in serum or plasma. Zonisamide (also known as ZONEGRAN® or 1,2-benzisoxazole- 3-methanesulfonamide) is an anti-convulsant drug used as an adjunctive therapy for patients with partial seizures. Quantification of zonisamide in patient samples can assist with therapy management decisions. n Dual liquid-stable reagent n Measuring range 2.00-50.00 µgl/ml n Excellent correlation with a turbidimetric method Pricing and Online Ordering at www.alphalabs.co.uk n freephone order 0800 387732 n buy online at www.alphalabs.co.uk 256 Technical information: Zonisamide in the patient sample competes with glucose-6-phosphate dehydrogenase (G6PDH) labelled drug in reagent 2 to bind the antibody in reagent 1. Binding of the labelled zonisamide reduces enzyme activity and therefore the rate of NAD to NADH conversion. Zonisamide Catalogue Number Description Pack Size 5022-0001-00 Zonisamide Assay 1x28ml, 1x14ml 5022-0002-00 Zonisamide Calibrator 1x4ml, 5x2ml 5022-0003-00 Zonisamide Controls 3x4ml ARK Diagnostics Anti-TNFα Monitoring Anti-TNFα drugs provide a major biotherapeutic breakthrough in the treatment of Chronic Inflammatory Rheumatism (CIR) such as Rheumatoid Arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis. They are also used for the treatment of Inflammatory Bowel Diseases when patients do not respond to steroids. These biomarkers bind TNFα blocking the action that is responsible for the inflammatory state. However, not all patients undergoing such treatment respond well and among those that do, the level of response can vary between patients and within the same individual over time. Theranostic tests provide a new approach for monitoring these biotherapies and a significant advance in the development of a customised and responsible treatment based on patient response. All LISA-TRACKER assays are enzyme linked immunoassays (ELISA) for the quantitative determination of human TNFα, drug specific anti-TNFα and anti-drug antibodies in human serum samples. These tests can be run separately or simultaneously using the same protocol. The LISA-Tracker DUO range combines assays for anti-TNFα drug concentrations and anti-drug antibody levels in one ELISA plate. Technical information: Anti-TNFα ELISA TNFα is coated onto a polystyrene microtiter plate. The diluted sample is added to the coated well. After incubation, unbound proteins are removed by washing. Anti-human IgG biotinylated antibodies are added. After incubation, unbound antibodies are removed by washing and horseradish peroxidase labelled streptavidin is added. The streptavidin binds to the complex formed with biotinylated anti-IgG antibodies. After incubation, the wells are washed again to eliminate any excess of conjugate. The bound enzyme is revealed by addition of substrate TMB (3,3’,5,5’ tetramethylbenzidin). The colour intensity is proportional to the amount of Anti-TNFα drug present. Adding H2SO4 (0.25M) stops the enzymatic reaction. The optical density is read by a spectrophotometer at 450nm. A range of calibration allows to define the quantity of Infliximab of each patient samples expressed in μg/mL. Anti-Drug Antibody ELISA The Anti-TNFα drug is coated onto a polystyrene microtiter plate. Diluted sample is added to the antibody coated well. After incubation, unbound proteins are removed by washing. Biotinylated drug (e.g. Infliximab) is added. After incubation, unbound antibodies are removed by washing then horseradish peroxydase labelled streptavidin is added. The streptavidin binds to the complex formed with biotinylated drug. After incubation, the wells are washed again to eliminate any excess conjugate. The bound enzyme is revealed by addition of substrate TMB (3,3’,5,5’ tetramethylbenzidin). The colour intensity is proportional to the amount of anti-drug antibodies in the sample. Adding H2SO4 (0.25M) stops the enzymatic reaction. After stopping the reaction by H2SO4 (0.25M), the optical density is read by a spectrophotometer at 450nm. A range of calibration allows definition of the quantity of anti-drug antibodies in each patient sample expressed in ng/mL. Anti-TNFα Monitoring Catalogue Number Description Pack Size LTI002-48 LISA-TRACKER Infliximab 48 tests LTA002-48 LISA-TRACKER Adalimumab 48 tests LTE002-48 LISA-TRACKER Etanercept 48 tests LTC002-48 LISA-TRACKER Certolizumab Pegol 48 tests LTG002-48 LISA-TRACKER Golimumab 48 tests LTI003-48 LISA-TRACKER anti-Infliximab 48 tests LTA003-48 LISA-TRACKER anti-Adalimumab 48 tests LTE003-48 LISA-TRACKER anti-Etanercept 48 tests LTC003-48 LISA-TRACKER anti-Certolizumab Pegol 48 tests LTG003-48 LISA-TRACKER anti-Golimumab 48 tests LTI005 LISA-TRACKER Duo Infliximab 2 x 48 tests LTA005 LISA-TRACKER Duo Adalimumab 2 x 48 tests LTE005 LISA-TRACKER Duo Etanercept 2 x 48 tests LTC005 LISA-TRACKER Duo Certolizumab Pegol 2 x 48 tests LTG005 LISA-TRACKER Duo Golimumab 2 x 48 tests Theradiag Assays are available for a range of specific Anti-TNFα drugs: ✓ Infliximab ✓ Adalimumab ✓ Etanercept ✓ Certolizumab ✓ Golimumab Clinical Chemistry - Therapeutic Drug Monitoring n Ready to use reagents n Common assay protocol for all assays n Quantitative results for anti-drug antibodies n Measuring range 0.1-8µg/ml for anti-TNFα


Catalogue_WEB_WoP_Jun16
To see the actual publication please follow the link above